NASDAQ:REVH Revolution Healthcare Acquisition (REVH) Stock Price, News & Analysis → Fidelity, Bezos, Goldman Bet Big on Tiny Biotech (From Behind the Markets) (Ad) Free REVH Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$10.04▼$10.0450-Day Range$10.01▼$10.0652-Week Range$9.62▼$10.50Volume371 shsAverage Volume183,205 shsMarket Capitalization$476.93 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Revolution Healthcare Acquisition alerts: Email Address Ad Behind the MarketsThe Weight Loss Pill That Could Disrupt a $32 Billion IndustryA revolutionary new weight loss pill is about to send shockwaves through the plus-size clothing market. Analysts are calling it the "King Kong" of diet drugs after amazing clinical trial results.Don't miss out on the "next Ozempic" >>> About Revolution Healthcare Acquisition Stock (NASDAQ:REVH)Revolution Healthcare Acquisition Corp. does not have significant operations. The company intends to acquire assets and businesses through a merger, share exchange, share purchase, reorganization, or similar business combination. It focuses on pursuing opportunities in health care, life sciences, and technology industries. The company was incorporated in 2021 and is based in Cambridge, Massachusetts.Read More Ad Behind the MarketsThe Weight Loss Pill That Could Disrupt a $32 Billion IndustryA revolutionary new weight loss pill is about to send shockwaves through the plus-size clothing market. Analysts are calling it the "King Kong" of diet drugs after amazing clinical trial results.Don't miss out on the "next Ozempic" >>> REVH Stock News HeadlinesMay 7, 2024 | marketwatch.comRevolution Bars Considering All Options After Rival Nightcap Shows InterestFebruary 4, 2024 | forbes.comReviewing 10 Of Healthcare Boldest Moves In Recent HistoryMay 8, 2024 | Behind the Markets (Ad)Could this Tiny Biotech End Disease Forever?Imagine a revolutionary treatment capable of editing out ANY disease. By literally "cutting" the genetic instructions that cause illness, and "pasting" in corrected DNA to restore perfect health.June 15, 2023 | dailymail.co.ukThe therapy revolutionJune 1, 2023 | finance.yahoo.comSyntax delivers index universes for Healthcare Innovations and Technology Revolution strategies on SmartTrust® UIT platformApril 26, 2023 | finance.yahoo.comHealthcare Revolution: Medical Tourism and the American DreamApril 25, 2023 | washingtonpost.comExecutive behind ChatGPT pushes for a new revolution: PsychedelicsJanuary 18, 2023 | msn.comHyderabad to host India’s first Fourth Industrial Revolution centre on healthcare, life sciencesMay 8, 2024 | Behind the Markets (Ad)Could this Tiny Biotech End Disease Forever?Imagine a revolutionary treatment capable of editing out ANY disease. By literally "cutting" the genetic instructions that cause illness, and "pasting" in corrected DNA to restore perfect health.October 7, 2022 | uk.finance.yahoo.comRevolution Healthcare Acquisition Corp. (REVH)August 13, 2022 | investing.comRevolution Healthcare Acquisition Corp (REVH)April 1, 2022 | nz.finance.yahoo.comPutin 'misled' by Russian military: White HouseMarch 30, 2022 | finance.yahoo.comWhat Kind Of Shareholders Hold The Majority In Revolution Healthcare Acquisition Corp.'s (NASDAQ:REVH) Shares?February 18, 2022 | nasdaq.comRevolution Healthcare Acquisition Corp. SAIL Class A Common Stock (REVH)See More Headlines Receive REVH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Revolution Healthcare Acquisition and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorUnclassified Industry Holding & other investment offices Sub-IndustryN/A Current SymbolNASDAQ:REVH CUSIPN/A CIK1841389 Webrevolutionhealthcareacqcorp.com Phone617-234-7000FaxN/AEmployees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$21.35 million Net MarginsN/A Pretax MarginN/A Return on Equity-81.90% Return on Assets3.65% Debt Debt-to-Equity RatioN/A Current Ratio2.68 Quick Ratio2.68 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash Flow$0.49 per share Price / Cash Flow20.62 Book Value($0.74) per share Price / Book-13.57Miscellaneous Outstanding Shares47,503,000Free Float46,919,000Market Cap$476.93 million OptionableNot Optionable Beta0.04 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. Jay S. Markowitz M.D. (Age 60)CEO & Director Mr. Mark A. McDonnell CPA (Age 53)CPA, Chief Financial Officer Mr. Paul Fielding (Age 35)Chief Operating Officer Mr. Jason Doren (Age 52)Chief Admin. Officer Key CompetitorsPrimavera Capital AcquisitionNYSE:PVTPG Pace Beneficial IINYSE:YTPGNabors Energy Transition Corp. IINASDAQ:NETDRigel Resource AcquisitionNYSE:RRACInflection Point Acquisition Corp. IINASDAQ:IPXXView All Competitors This page (NASDAQ:REVH) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyAI “wealth window” is closing June 25thParadigm PressElon Musk Secret Crypto Plot ExposedCrypto 101 MediaThe AI Stock that’s Disrupting Every IndustryStockEarningsShocking: One AI startup's revenue could surge 4,735%Manward PressForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsCharles Payne Demystifies OptionsUnstoppable Prosperity Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Revolution Healthcare Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
